
Quarterly report 2022-Q1
added 12-16-2023
R1 RCM Financial Ratios 2011-2025 | RCM
Annual Financial Ratios R1 RCM
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
74.5 | 27.3 | 114.1 | -23.6 | -11.4 | 1.4 | -3.0 | -7.0 | - | - | - |
P/S |
4.9 | 2.5 | 1.2 | 1.2 | 1.5 | 0.4 | 2.2 | 2.7 | - | - | - |
EPS |
-1.9 | 0.4 | -0.1 | -0.6 | -0.8 | 0.7 | -0.9 | -0.8 | 1.4 | -1.2 | -0.7 |
EV (Enterprise Value) |
8.21 B | 3.87 B | 1.96 B | 1.6 B | 618 M | 315 M | 824 M | 1 B | 367 M | 617 M | -70.6 M |
EBITDA per Share |
0.84 | 1.28 | 1.02 | 0.08 | -0.11 | 3.28 | -1.22 | -0.374 | - | - | - |
EV/EBITDA |
36.6 | 15.5 | 11.9 | 33.2 | -57.1 | 0.2 | -1.3 | -11.6 | - | - | - |
PEG |
0.42 | 0.25 | 0.75 | -0.95 | 0.04 | 11.33 | -24.28 | -56.15 | - | - | - |
P/B |
20.9 | 9.4 | 5.5 | 5.0 | 3.0 | 1.5 | -1.2 | -3.9 | - | - | - |
P/CF |
27.3 | 51.8 | 12.0 | 58.5 | 32.0 | -2.4 | -5.6 | -6.7 | - | - | - |
ROE % |
28.04 | 133.22 | 66.30 | -719.05 | -176.05 | 111.18 | 39.50 | 55.97 | - | - | - |
ROA % |
6.71 | 9.85 | 1.29 | -5.61 | -17.50 | 42.66 | -18.31 | -17.84 | - | - | - |
ROCE % |
42.02 | 8.14 | 12.34 | -7.55 | -48.42 | 106.52 | -59.66 | -70.05 | - | - | - |
Current Ratio |
1.3 | 1.4 | 1.4 | 1.4 | 3.0 | 1.5 | 0.5 | 0.9 | - | - | - |
DSO |
27.5 | 20.6 | 14.5 | 10.6 | 4.9 | 3.6 | 31.7 | 7.7 | - | - | - |
DPO |
5.6 | 6.9 | 5.6 | 4.0 | 6.6 | 14.5 | 11.5 | 25.0 | - | - | - |
Operating Cycle |
27.6 | 20.6 | 14.5 | 10.6 | 4.9 | 3.6 | 31.7 | 7.7 | - | - | - |
Cash Conversion Cycle |
21.9 | 13.8 | 9.0 | 6.5 | -1.7 | -10.9 | 20.3 | -17.3 | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios R1 RCM
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
- | - | - | 0.11 | - | 0.06 | 0.07 | -2.37 | - | - | 0.04 | 0.06 | 0.01 | 0.02 | -0.09 | -0.04 | -0.1 | -0.17 | -0.07 | -0.26 | -0.44 | -0.08 | -0.11 | -0.12 | 0.05 | 0.18 | -0.45 | 0.85 | 0.06 | -0.34 | -0.27 | -0.32 | -0.18 | 0.1 | -0.18 | -0.57 | 0.07 | -0.39 | 1.96 | -0.28 | -0.3 | -0.32 | -0.32 | -0.28 | -0.01 | -0.23 | -0.25 | -0.26 |
EBITDA per Share |
- | - | - | 0.22 | - | 0.14 | 0.12 | 0.23 | - | 0.53 | 0.51 | 0.42 | 0.13 | 0.57 | 0.34 | 0.18 | 0.04 | 0.2 | -0.04 | -0.06 | -0.04 | -0.01 | -0.06 | -0.05 | 0.26 | 0.64 | -0.68 | 2.86 | 0.1 | -0.54 | -0.42 | -0.5 | -0.32 | 0.17 | -0.27 | -0.87 | 0.1 | -0.58 | 3.15 | -0.43 | -0.49 | -0.48 | -0.49 | -0.42 | - | -0.32 | -0.38 | -0.42 |
ROE % |
16.04 | 21.13 | 18.20 | 23.91 | 19.90 | 28.22 | 31.45 | 58.49 | 98.85 | 141.95 | 195.79 | 134.30 | 81.79 | -51.78 | -326.64 | -343.94 | -719.05 | -748.93 | -547.01 | -521.04 | -176.05 | -162.19 | -454.67 | -102.90 | -1439.02 | -1335.07 | -1016.37 | -1335.75 | 39.50 | 54.47 | 32.29 | 31.78 | 55.98 | 36.11 | 86.71 | -144.39 | -151.94 | -132.25 | -158.35 | 83.39 | 77.15 | 65.50 | 38.39 | 5.87 | -29.28 | -9.33 | -10.06 | -10.48 |
ROA % |
4.09 | 5.24 | 4.34 | 5.90 | 4.98 | 5.41 | 4.70 | 4.46 | 3.69 | 4.52 | 5.08 | 3.20 | 1.29 | -0.25 | -2.90 | -2.70 | -5.61 | -16.87 | -16.28 | -17.92 | -17.50 | -2.38 | 7.68 | -0.16 | 42.64 | 40.67 | 24.52 | 28.64 | -18.31 | -23.44 | -14.14 | -12.19 | -17.84 | -12.63 | -22.14 | 18.44 | 25.51 | 19.07 | 20.72 | -21.96 | -22.17 | -17.11 | -17.50 | -18.21 | -19.66 | -6.10 | -6.58 | -6.85 |
ROCE % |
23.57 | 32.88 | 30.40 | 38.97 | 30.85 | 47.81 | 55.46 | 101.34 | 174.26 | 253.27 | 395.77 | 409.83 | 501.71 | 484.61 | 233.09 | -116.37 | -482.54 | -555.52 | -478.73 | -228.31 | -82.34 | -294.83 | -778.75 | -180.73 | -2421.14 | -2202.68 | -1677.78 | -2225.45 | 63.78 | 91.10 | 55.02 | 54.33 | 90.45 | 56.62 | 138.17 | -228.50 | -238.40 | -206.93 | -248.80 | 137.84 | 132.08 | 112.16 | 67.39 | 11.98 | -48.69 | -15.46 | -16.33 | -16.83 |
Current Ratio |
- | - | - | 1.3 | 1.3 | 1.3 | 1.4 | 1.3 | 1.4 | 1.3 | 1.3 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 | 3.0 | 3.0 | 3.0 | 3.0 | 1.6 | 1.6 | 1.6 | 1.6 | 0.7 | 0.7 | 0.7 | 0.7 | 0.8 | 0.8 | 0.8 | 0.8 | 0.9 | 0.9 | 0.9 | 0.9 | 0.7 | 0.8 | 0.8 | 0.8 | 0.8 | 2.9 | 2.9 | 2.9 |
DSO |
- | - | - | 29.2 | - | 25.3 | 25.1 | 25.2 | - | 27.1 | 26.5 | 20.4 | 15.2 | 15.8 | 16.2 | 15.6 | 14.7 | 15.4 | 18.5 | 15.6 | 5.3 | 6.1 | 7.5 | 6.4 | - | 16.1 | - | 1.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.2 | 8.5 | 6.8 | 19.5 | 39.2 | 46.8 | - |
DPO |
- | - | - | 6.0 | - | 6.5 | 7.0 | 7.0 | - | 8.2 | 9.0 | 8.1 | - | 7.6 | 7.5 | 5.8 | - | 4.1 | 4.8 | 5.6 | - | 5.9 | 6.8 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Cycle |
- | - | - | 29.2 | - | 25.3 | 25.1 | 25.2 | - | 27.1 | 26.5 | 20.4 | 15.2 | 15.8 | 16.2 | 15.6 | 14.7 | 15.4 | 18.5 | 15.6 | 5.3 | 6.1 | 7.5 | 6.4 | - | 16.1 | - | 1.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.2 | 8.5 | 6.8 | 19.5 | 39.2 | 46.8 | - |
Cash Conversion Cycle |
- | - | - | 23.2 | - | 18.8 | 18.1 | 18.2 | - | 18.9 | 17.5 | 12.3 | 15.2 | 8.2 | 8.7 | 9.8 | 14.7 | 11.3 | 13.8 | 10.0 | 5.3 | 0.2 | 0.7 | 6.4 | - | 16.1 | - | 1.9 | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.2 | 8.5 | 6.8 | 19.5 | 39.2 | 46.8 | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company R1 RCM , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Health information services industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Cerner Corporation
CERN
|
- | - | $ 27.9 B | ||
|
Computer Programs and Systems
CPSI
|
- | 4.4 % | $ 133 M | ||
|
Covetrus
CVET
|
- | - | $ 2.94 B | ||
|
Accolade
ACCD
|
- | 0.29 % | $ 206 M | ||
|
Castlight Health, Inc.
CSLT
|
- | -7.28 % | $ 227 M | ||
|
HMS Holdings Corp.
HMSY
|
- | - | $ 3.29 B | ||
|
Inovalon Holdings, Inc.
INOV
|
- | - | $ 6.37 B | ||
|
Change Healthcare
CHNG
|
- | - | $ 9.03 B | ||
|
Evolent Health
EVH
|
$ 4.11 | -0.48 % | $ 385 M | ||
|
Health Catalyst
HCAT
|
$ 2.34 | -4.82 % | $ 141 M | ||
|
HealthStream
HSTM
|
$ 24.4 | 0.95 % | $ 741 M | ||
|
iCAD
ICAD
|
- | - | $ 102 M | ||
|
Akerna Corp.
KERN
|
- | - | $ 161 M | ||
|
HealthEquity
HQY
|
$ 96.06 | -0.75 % | $ 8.22 B | ||
|
OptimizeRx Corporation
OPRX
|
$ 13.18 | -1.35 % | $ 226 M | ||
|
American Well Corporation
AMWL
|
$ 4.68 | 1.3 % | $ 70.2 M | ||
|
Allscripts Healthcare Solutions
MDRX
|
- | -10.39 % | $ 886 M | ||
|
Progyny
PGNY
|
$ 26.39 | -1.2 % | $ 2.26 B | ||
|
Premier
PINC
|
$ 28.26 | - | $ 2.33 B | ||
|
MTBC
MTBC
|
- | -0.58 % | $ 51.7 M | ||
|
GoodRx Holdings
GDRX
|
$ 2.72 | -3.72 % | $ 1.05 B | ||
|
Schrödinger
SDGR
|
$ 18.41 | 1.99 % | $ 1.34 B | ||
|
Omnicell
OMCL
|
$ 43.31 | -1.25 % | $ 1.99 B | ||
|
1Life Healthcare
ONEM
|
- | - | $ 3.37 B | ||
|
Phreesia
PHR
|
$ 16.68 | 2.71 % | $ 910 M | ||
|
So-Young International
SY
|
$ 2.92 | -5.66 % | $ 232 M | ||
|
Signify Health
SGFY
|
- | -0.02 % | $ 7.21 B | ||
|
10x Genomics
TXG
|
$ 15.77 | 2.01 % | $ 1.85 B | ||
|
NantHealth
NH
|
- | -46.64 % | $ 10.4 M | ||
|
NextGen Healthcare
NXGN
|
- | - | $ 1.6 B | ||
|
Veeva Systems
VEEV
|
$ 219.17 | -1.81 % | $ 35.2 B | ||
|
Zhongchao
ZCMD
|
$ 0.58 | -3.18 % | $ 3.02 M | ||
|
Streamline Health Solutions
STRM
|
- | - | $ 21.4 M | ||
|
Teladoc Health
TDOC
|
$ 7.36 | -2.65 % | $ 1.26 B | ||
|
Tabula Rasa HealthCare
TRHC
|
- | - | $ 255 M | ||
|
SCWorx Corp.
WORX
|
$ 0.21 | 5.86 % | $ 306 K |